On August 14, ALI HEALTH fell 3.17% in regular trading, trading at HK$3.21/share, with turnover of HK$138 million. The decline came amid broad-based selling pressure across Hong Kong-listed internet and direct retail stocks.

On the news front, major US tech companies have been releasing earnings in quick succession over recent weeks, triggering volatile swings that have spilled over into Asian tech names. Domestically, internet giants including Tencent, JD.com, Alibaba, and Meituan are set to report results imminently, fueling a wait-and-see posture among investors. Within the same sector, JD-SW fell 9.19%, JD Health fell 6.07%, Meituan-W fell 3.12%, and BABA-W fell 2.21%.

Adding to the overhang, UBS previously maintained a Sell rating on ALI HEALTH and cut its target price to HK$3.1, trimming earnings forecasts for fiscal years 2027-2029 by 5%, which continues to weigh on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)